• View the Talks
• 64 min
  1. Current trends in antiviral drug development

  • Prof. Dr. Erik De Clercq
• 76 min
  2. Antivirals versus vaccines

  • Prof. Albert D.M.E. Osterhaus
• 58 min
  3. Prospects of anti-HIV therapy and prophylaxis

  • Prof. Dr. Erik De Clercq
• 38 min
  4. Systemic RNA interference (RNAi) therapeutics for the treatment of HIV-1

  • Prof. John Rossi
• 9 min
  5. The path towards a cure for chronic hepatitis B

  • Prof. Fabien Zoulim
• 70 min
  6. Influenza antivirals: update

  • Prof. Frederick G. Hayden
• 35 min
  7. Herpes simplex virus and varicella-zoster virus helicase-primase inhibitors

  • Dr. Hugh J. Field
• 45 min
  8. Nucleoside phosphonates as inhibitors of HIV

  • Dr. Tomas Cihlar
• 59 min
  9. HIV-1 integrase inhibitors

  • Prof. Martin Markowitz
• 52 min
  10. Cellular cofactors of HIV integrase: from target identification to discovery of ledgins

  • Prof. Zeger Debyser
• 32 min
  11. HIV entry inhibitors

  • Prof. José Esté
• 39 min
  12. Antiviral therapy of orthopoxvirus infection

  • Prof. Earl R. Kern
  • Prof. Mark N. Prichard
• 25 min
  13. Herpes simplex virus antiviral chemotherapy

  • Dr. Hugh J. Field
• 30 min
  14. Cyclophilin inhibitors for HCV

  • Prof. Robert Flisiak
• Archived Lectures *These may not cover the latest advances in the field
• 50 min
  15. Towards the development of potent therapy against the hepatitis C virus

  • Prof. Johan Neyts
• 62 min
  16. Antiviral therapy of chronic hepatitis B virus infections: is resistance still a challenge?

  • Prof. Fabien Zoulim

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Infectious disease-related mortality rates trends
3. Emerging infections in the past decades
4. Newly identified human respiratory viruses
5. The AIDS pandemic
6. Combating viruses
7. HIV vaccine approaches
8. Generating HIV vaccine problems
9. Antibodies enhance infection susceptibility
10. Vaccination increases virus susceptibility
11. Discouraging results STEP trial
12. Conclusions - HIV vaccines
13. Positive results in HIV trial in humans
14. Vaccine development effort conclusions
15. Introduction of antivirals use against HIV
16. Anti-HIV therapy
17. HIV anti-retroviral drugs
18. Anti-HIV therapy 2011
19. HIV landscape: launches and patent expirations
20. Paramyxovirus family- Morbilliviruses
21. Koch's postulates for PDV etiology in seals
22. Morbilliviruses crossing the species barrier
23. Paramyxovirus family- Metapneumovirus
24. Newly discovered human paramyxovirus- hMPV
25. Human metapneumovirus
26. SARS-CoV
27. Cynomolgus macaques
28. Press conference of SARS etiology network
29. Candidate SARS vaccines
30. Macaques vaccination - inactivated SARS CoV (1)
31. Macaques vaccination - inactivated SARS CoV (2)
32. Macaques vaccination - inactivated SARS CoV (3)
33. IFN-alpha treatment macaques
34. Gross pathology in aged macaques
35. IFN-alpha effect in aged macaques
36. Bats are carriers of many viruses
37. Paramyxovirus family- Henipahvirus
38. Human-to-human transmission
39. Smallpox
40. History of smallpox vaccination
41. Edward Jenner 1749-1824
42. Production of first generation smallpox vaccine
43. First publication on "vaccination" (1798)
44. Antiviral drugs against smallpox
45. Antiviral activity spectrum of cidofovir
46. Mechanism of action of cidofovir
47. Other acyclic nucleoside phosphonate analogues
48. Antiviral effect after lethal MPXV infection
49. Human influenza: three appearances
50. Influenza A virus origin
51. Influenza A virus- recent zoonotic transmissions
52. H7N7 in the Netherlands 2003- Human cases
53. H5N1 avian influenza virus endemic areas
54. Last four pandemics
55. Avian influenza A virus- adaptation
56. 2009 influenza A (H1N1) virus: relevant mutations
57. Diagnostic read-outs in the ferret model
58. The Mexican flu virus
59. The Mexican flu virus origin
60. Examples influenza H1N1v vaccines
61. Assessment of pre-pandemic H5N1 clinical trials
62. The importance of an adjuvant
63. Ferrets vaccinated with adjuvanted H5N1 vaccine
64. Seasonal vaccine and pandemic A/H1N1
65. Live attenuated vaccines against H1N1 influenza
66. Evaluation in cynomolgus macaques
67. Reduction of virus replication using vaccines (1)
68. Reduction of virus replication using vaccines (2)
69. What are the targets for flu drugs?
70. Oseltamivir resistance
71. Spontaneous H1N1 oseltamivir resistance
72. 2009 pandemic influenza A (H1N1) virus mutations
73. Conclusions

Topics Covered

• Emerging infections in the past decades
• Human respiratory viruses
• The AIDS pandemic
• HIV vaccine approaches
• Antivirals use against HIV
• Morbilliviruses
• Metapneumovirus
• hMPV
• SARS-CoV
• Candidate SARS vaccines
• Vaccination of macaques against SARS
• Henipahvirus
• Smallpox
• History of smallpox vaccination
• Antiviral drugs against smallpox
• Cidofovir
• Human influenza: three appearances
• Avian influenza A virus: adaptation
• H1N1 virus: relevant mutations
• The Mexican flu virus
• Pre-pandemic H5N1 clinical trials
• The importance of an adjuvant
• Seasonal vaccine and pandemic A/H1N1
• Flu drugs targets

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases
• Vaccines

Talk Citation

Publication History

• Published on August 30, 2011

Financial Disclosures

• Prof. Albert D.M.E. Osterhaus has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.